| Literature DB >> 35625125 |
Romeo T Cristina1, Rudolf Kocsis1,2, János Dégi1, Florin Muselin1, Eugenia Dumitrescu1, Emil Tirziu1, Viorel Herman1, Aurel P Darău3, Ion Oprescu1.
Abstract
Reptiles are potential reservoirs of bacteria that could be transmitted, thus becoming a zoonotic hazard. (1) Background: This three-year investigation surveyed the pathological status of 398 pet reptiles: chelonians, snakes (venomous/non-venomous), and lizards. The main pathological entities found were related to the skin, the sensory organs, the digestive system, the respiratory system, the cardiovascular system, the urinary system, the genitalia, the osteo-muscular tract, surgical issues, tumors, and intoxications. (2)Entities:
Keywords: antibiotic sensitivity; bacterial load; pathology; pet-reptiles
Year: 2022 PMID: 35625125 PMCID: PMC9137941 DOI: 10.3390/ani12101279
Source DB: PubMed Journal: Animals (Basel) ISSN: 2076-2615 Impact factor: 3.231
Presentation of cases: bacterial media, reptiles, and antibiotics tested.
| No. | Bacterial Strain | Isolates | From Total% | Sampled | Reptile |
|---|---|---|---|---|---|
| 1 |
| 1 | 2.32 | oral cavity |
|
| 2 |
| 1 | 2.32 | respiratory tract |
|
| 3 |
| 1 | 2.32 | s.c. abscess |
|
| 4 |
| 1 | 2.32 | oral cavity |
|
| 5 |
| 1 | 2.32 | oral cavity |
|
| 6 |
| 2 | 4.65 | trachea |
|
| feces |
| ||||
| 7 |
| 1 | 2.32 | dermal wound |
|
| 8 |
| 1 | 2.32 | trachea |
|
| 9 |
| 1 | 2.32 | oral cavity |
|
| 10 |
| 1 | 2.32 | trachea |
|
| 11 |
| 2 | 4.65 | respiratory tract |
|
| oral cavity |
| ||||
| 12 |
| 6 | 13.95% | oral cavity |
|
| oral cavity |
| ||||
| trachea |
| ||||
| trachea |
| ||||
| s.c. abscess |
| ||||
| dermal abscess |
| ||||
| 13 |
| 3 | 6.97 | oral cavity |
|
| trachea |
| ||||
| trachea |
| ||||
| 14 |
| 3 | 6.97 | trachea |
|
| oral cavity |
| ||||
| dermal abscess |
| ||||
| 15 | 1 | 2.32 | trachea |
| |
| 16 |
| 2 | 4.65 | dermal abscess |
|
| feces |
| ||||
| 17 |
| 2 | 4.65 | trachea |
|
| kidney |
| ||||
| 18 |
| 5 | 11.62 | trachea |
|
| oral cavity |
| ||||
| oral cavity |
| ||||
| dermal abscess |
| ||||
| dermal wound |
| ||||
| 19 | 2 | 4.65 | oral cavity |
| |
| feces |
| ||||
| 20 |
| 1 | 2.32 | oral cavity |
|
| 21 |
| 4 | 9.30 | trachea |
|
| trachea |
| ||||
| oral cavity |
| ||||
| oral cavity |
| ||||
| 22 |
| 1 | 2.32 | s.c. formation at the tail’s base |
|
Antimicrobial susceptibility testing using VITEK®2 AST GN67 and GP69 cards. Beta-lactams and Cephalosporins: Amoxicillin; Amikacin; Penicillin; Oxacillin; Cefazolin; Cefaclor; Cefalexin; Cephalothin; Cefuroxime; Ceftazidime; Cefovecin; Cefquinome; Aminoglycosides: Gentamicin; Kanamycin; Neomycin; Macrolides: Erythromycin, Azithromycin; Tulathromycin; Lincomycin; Clindamycin; Mupirocin; Fucidin; Quinolones: Enrofloxacin; Ciprofloxacin; Marbofloxacin; Orbifloxacin; Pradofloxacin; Tetracyclines and Chloramphenicol: Tetracycline; Doxycycline; Chloramphenicol; Florphenicol; Polymyxins: Polymyxin B, Colistin; Sulfonamides and Trimethoprim.
Figure 1Comparing the incidence of digestive diseases and other diseases within the reptile category as diagnosed in this study (where: ** means p < 0.01).
Figure 2Comparative disease distribution/no. of cases/reptile species/disease types; comparison of chelonians vs. venomous and non-venomous snakes (where *** means p < 0.001) and lizards vs. venomous and non-venomous snakes (where ** means p < 0.01, and *** means p < 0.001).
Figure 3The incidence of digestive diseases (the most common—left image) and skin diseases (the second most common—right image); comparison of chelonians vs. snakes (where ** means p <0.01); lizards/snakes (where ## means p < 0.01) and lizards vs. chelonians and snakes (where ** means p < 0.01.).
Results of antibiogram/distribution of bacterial strains (susceptible/resistant/antibacterial) used.
| Isolated Bacterial Strains/No. | Strains | Antibiotic/Group/Generation | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
| 2. |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
| 4. |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
| 5. |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
| 6. |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
| 7. |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
| 8. |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
| 9. |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
| 10. |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
| 11. |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
| 12. |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
| 13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
| 14. |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
| 15. |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
| 16. |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
| 17. |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
| 18. | 1 |
|
|
|
|
|
|
|
|
|
|
|
|
| |||
| 19 | 2 |
|
|
|
|
|
|
|
|
|
|
|
|
| |||
| 20 | 1 |
|
|
|
|
|
|
|
|
|
|
|
|
| |||
| 21. | 1 |
|
|
|
|
|
|
|
|
|
|
|
|
| |||
| 22. | 1 |
|
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
|
| Total | ||||||||||||||
Legend: R—resistant; S—sensitive; I—intermediate. PEN = penicillin; CEF 1, 2, 3, 4 = cephalosporin (from generation 1, 2, 3 or 4); MAC = macrolides; LINC = lincosamides; AMGL = aminoglycosides; QUIN = quinolones; TETR = tetracycline; S + T = sulfonamides + trimethoprim; CLO = chloramphenicol; FLO = florphenicols.